<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752882</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0025</org_study_id>
    <nct_id>NCT00752882</nct_id>
  </id_info>
  <brief_title>Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration</brief_title>
  <official_title>Comparison of Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Meningitis is an infection where morbidity and mortality depend on the delay of the initial&#xD;
      treatment for a good prognostic. The antibiotherapy rapidity allows to decrease the&#xD;
      mortality. Intermittent administration of ceftazidime is a reference treatment of Pseudomonas&#xD;
      aeruginosa meningitis. In the case of Pseudomonas aeruginosa pneumopathy, ceftazidime can be&#xD;
      administered by intermittent injections or by continuous perfusion. The continuous&#xD;
      administration of ceftazidime is not validated in Pseudomonas aeruginosa meningitis. However,&#xD;
      ceftazidime is a time dependant antibiotic and continuous treatment would provide a more&#xD;
      efficient therapeutic. The aim of this study is to determine if the continuous administration&#xD;
      of ceftazidime could permit a better therapeutic practice of Pseudomonas aeruginosa&#xD;
      meningitis compared with intermittent administrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the administration of ceftazidime by intermittent intravenous&#xD;
      injections (29 mg/kg 30min Ã—3/day) and by continuous infusion (86 mg/kg/24 h, preceded by 29&#xD;
      mg/kg/30 min). The main evaluation criterion of the study is the measure of the time during&#xD;
      which ceftazidime concentration is above minimal inhibitive concentration of Pseudomonas&#xD;
      aeruginosa in cerebrospinal fluid. This study will be developed in a neurological intensive&#xD;
      care department. Inclusion criteria will be essentially, patients aged over 18 years old,&#xD;
      hospitalised for a cerebrolesion associated to a hydrocephalus drained by an external&#xD;
      ventricular derivation, an acquired pneumopathy under mechanic ventilation since more 7 days&#xD;
      in the department of neurological intensive care. This study is a prospective randomised,&#xD;
      simple blind and divided in two parts. The first part of the study is a study with parallel&#xD;
      group comparing the treatment initiation between a continuous and an intermittent treatment&#xD;
      of ceftazidime. The second part of the study is a cross-over study. One patient group will&#xD;
      receive a continuous treatment of ceftazidime and the other patient group will receive an&#xD;
      intermittent treatment of ceftazidime.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <completion_date type="Anticipated">June 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pseudomonas Aeruginosa Meningitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftazidime</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients aged over 18 years old,&#xD;
&#xD;
          -  patients hospitalised for a cerebrolesion associated to a hydrocephalus drained by an&#xD;
             external ventricular derivation, an acquired pneumopathy under mechanic ventilation&#xD;
             since more 7 days in the department of neurological intensive care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients treated by ceftazidime 15 days before the beginning of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Tarbouriech, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Lacarin, DRC</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Patrick LACARIN</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Ceftazidime</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pseudomonas</keyword>
  <keyword>aeruginosa</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Patients</keyword>
  <keyword>hospitalised</keyword>
  <keyword>cerebrolesion</keyword>
  <keyword>acquired</keyword>
  <keyword>pneumopathy</keyword>
  <keyword>mechanic</keyword>
  <keyword>ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

